FAQ: Cybin's EMBRACE Phase 3 Study Approval in Australia for CYB003 Treatment
Summary
What is the main announcement in this content?
Cybin Inc. has received approval in Australia to conduct the EMBRACE study, which is the second pivotal trial in its Phase 3 multinational program called PARADIGM, evaluating CYB003, a proprietary deuterated psilocin analog.
Why is this approval significant for Cybin and mental health treatment?
This approval allows Cybin to advance its clinical development of CYB003 for major depressive disorder, representing progress in developing innovative, intermittent treatments that could provide long-lasting results for mental health conditions with large unmet needs.
How did Cybin receive approval to conduct this study in Australia?
Approval was granted through Australia’s Clinical Trial Notification scheme, with clearance from multiple Ethics Committees of the Australian Therapeutics Goods Administration and Research Governance Offices.
What is CYB003 and what condition is it being developed to treat?
CYB003 is Cybin’s proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder.
What other treatments is Cybin developing besides CYB003?
Cybin is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, and has a research pipeline of investigational, 5-HT-receptor focused compounds.
Where is Cybin operational besides Australia?
Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland, in addition to now conducting studies in Australia.
Where can investors find the latest news and updates about Cybin?
The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
What is the EMBRACE study part of in Cybin’s development program?
The EMBRACE study is the second pivotal trial in PARADIGM, which is Cybin’s Phase 3 multinational program evaluating CYB003 for mental health treatment.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 181783